2-Naphthalenesulphanyl-L-aspartyl-2-(phenethyl) amide (2-NAP) and food intake in rats: evidence that endogenous peripheral CCK does not play a major role as a satiety factor

British Journal of Pharmacology
I S Ebenezer, B A Baldwin

Abstract

1. The demonstration that systemic administration of the CCKA receptor antagonist, devazepide, increases food intake in rats has provided the strongest support for the hypothesis that endogenous peripherally released cholecystokinin (CCK) acts as a satiety factor. However, interpretation of these results has been confounded by the fact that devazepide can enter the brain from the systemic circulation and may increase food intake by a central action. The present study was therefore undertaken to confirm the hypothesis that endogenous peripheral CCK is a satiety factor by investigating the effects of a novel CCKA receptor antagonist, 2-NAP, which is unlikely to cross the blood brain barrier, on food intake in rats. 2. 2-NAP (1-16 mg kg-1, i.p.) had no significant effects on the intake of a test meal in rats. 3. Pretreatment of rats with 2-NAP (2 mg kg-1, s.c.) abolished the inhibitory effects of exogenous peripheral CCK (5 micrograms kg-1, i.p.) on food intake. 4. In agreement with previous results, devazepide (50-200 micrograms kg-1, i.p.) significantly increased the intake of a test meal in rats. 5. The observations that 2-NAP, which is unlikely to penetrate the blood brain barrier, had no effect on food intake, but that 2-NAP ...Continue Reading

References

Nov 1, 1979·Physiology & Behavior·J D FalascoJ Gibbs
Jul 1, 1991·Neuropeptides·G N WoodruffJ Hughes
Mar 30, 1990·Science·A WellerJ Gibbs
Jan 1, 1990·Physiology & Behavior·I S EbenezerB A Baldwin
Oct 1, 1987·The Journal of Pharmacy and Pharmacology·R G Pullen, O J Hodgson
Jul 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·R S Chang, V J Lotti
Sep 1, 1973·Journal of Comparative and Physiological Psychology·J GibbsG P Smith
Feb 1, 1981·The American Journal of Clinical Nutrition·H R KissileffG P Smith
Jul 1, 1981·Physiology & Behavior·B Gosnell, S Hsiao
Jan 1, 1994·Peptides·J N Crawley, R L Corwin
Jun 1, 1994·Pharmacology, Biochemistry, and Behavior·M Covasa, J M Forbes
Mar 23, 1994·Annals of the New York Academy of Sciences·G P Smith, J Gibbs
May 1, 1993·Neuroreport·I S Ebenezer, R F Parrott

❮ Previous
Next ❯

Citations

Jul 29, 2005·Cellular and Molecular Neurobiology·Rosalinda Guevara-GuzmánRaymond Nowak
Sep 30, 1999·The Journal of Pharmacy and Pharmacology·T A WoltmanR D Reidelberger
Nov 23, 2007·European Journal of Pharmacology·Jayesh D Patel, Ivor S Ebenezer
Jul 10, 2007·British Journal of Pharmacology·I VerbaeysM Cokelaere
Nov 5, 2002·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Roger D ReidelbergerMartin Hulce
May 10, 2003·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Roger D ReidelbergerMartin Hulce

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.